A genome-wide association study of inflammatory biomarker changes in response to fenofibrate treatment in the Genetics of Lipid Lowering Drug and Diet Network

Objective Despite the evidence in support of the anti-inflammatory and triglyceride-lowering effects of fenofibrate, little is known about genetic determinants of the observed heterogeneity in treatment response. This study provides the first genome-wide examination of fenofibrate effects on systemic inflammation. Methods Biomarkers of inflammation were measured in participants of the Genetics of Lipid Lowering Drugs and Diet Network (n=1092) before and after a 3-week daily treatment with 160 mg of fenofibrate. Two inflammatory patterns [high-sensitivity C-reactive protein-interleukin-6 and monocyte chemoattractant protein-1-tumor necrosis factor (MCP1-TNF-&agr;)] were derived using principal component analysis. Associations between single nucleotide polymorphisms on the Affymetrix 6.0 chip and phenotypes were assessed using mixed linear models, adjusted for age, sex, study center, and ancestry as fixed effects and pedigree as a random effect. Results Before fenofibrate treatment, the strongest evidence for association was observed for polymorphisms near or within the IL2RA gene with the high-sensitivity C-reactive protein-interleukin-6 (IL6) pattern (rs7911500, P=5×10−9 and rs12722605, P=5×10−8). Associations of the MCP1-TNF-&agr; pattern with loci in several biologically plausible genes [CYP4F8 (rs3764563), APBB1IP (rs1775246), COL13A1 (rs2683572), and COMMD10 (rs1396485)] approached genome-wide significance (P=3×10−7, 5×10−7, 6×10−7, and 7×10−7, respectively) before fenofibrate treatment. After fenofibrate treatment, the rs12722605 locus in IL2RA was also associated with the MCP1-TNF-&agr; pattern (P=3×10−7). The analyses of individual biomarker response to fenofibrate did not yield genome-wide significant results, but the rs6517147 locus near the immunologically relevant IFNAR2 gene was suggestively associated with IL6 (P=7×10−7). Conclusion We have identified several novel biologically relevant loci associated with systemic inflammation before and after fenofibrate treatment.

[1]  M. Clerici,et al.  Serum DNA motifs predict disease and clinical status in multiple sclerosis. , 2010, Journal of Molecular Diagnostics.

[2]  Joshua M. Korn,et al.  Integrated genotype calling and association analysis of SNPs, common copy number polymorphisms and rare CNVs , 2008, Nature Genetics.

[3]  A. O’Garra,et al.  Regulatory T cells and mechanisms of immune system control , 2004, Nature Medicine.

[4]  O. Cummings,et al.  Genome-wide association study identifies variants associated with histologic features of nonalcoholic Fatty liver disease. , 2010, Gastroenterology.

[5]  A. Schäffer,et al.  Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. , 2009, The New England journal of medicine.

[6]  G. Schmitz,et al.  Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapy , 2007, Current opinion in lipidology.

[7]  M. Sabatine,et al.  Genetic variants in the KIF6 region and coronary event reduction from statin therapy , 2010, Human Genetics.

[8]  J. Voyich,et al.  Prevention of Bone Marrow Cell Apoptosis and Regulation of Hematopoiesis by Type I IFNs during Systemic Responses to Pneumocystis Lung Infection , 2011, The Journal of Immunology.

[9]  D. Arnett,et al.  Effect of influenza vaccine on markers of inflammation and lipid profile. , 2005, The Journal of laboratory and clinical medicine.

[10]  J. Todd,et al.  Association of the interleukin‐2 receptor alpha (IL‐2Rα)/CD25 gene region with Graves’ disease using a multilocus test and tag SNPs , 2007, Clinical endocrinology.

[11]  D Spiegelman,et al.  Prospective study of major dietary patterns and risk of coronary heart disease in men. , 2000, The American journal of clinical nutrition.

[12]  G. Freeman,et al.  RIAM, an Ena/VASP and Profilin ligand, interacts with Rap1-GTP and mediates Rap1-induced adhesion. , 2004, Developmental cell.

[13]  R. Jacobson,et al.  Immunogenetics of seasonal influenza vaccine response. , 2008, Vaccine.

[14]  P. Libby,et al.  Inflammation in Diabetes Mellitus: Role of Peroxisome Proliferator-Activated Receptor–α and Peroxisome Proliferator-Activated Receptor–γ Agonists , 2007 .

[15]  Y. Bossé,et al.  Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients. , 2002, Pharmacogenetics.

[16]  M. Bragt,et al.  Comparison of the effects of n-3 long chain polyunsaturated fatty acids and fenofibrate on markers of inflammation and vascular function, and on the serum lipoprotein profile in overweight and obese subjects. , 2012, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[17]  O. Kallioniemi,et al.  Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer. , 2011, The American journal of pathology.

[18]  I. Borecki,et al.  Smoking, inflammatory patterns and postprandial hypertriglyceridemia. , 2009, Atherosclerosis.

[19]  I. Borecki,et al.  Apolipoprotein B genetic variants modify the response to fenofibrate: a GOLDN study[S] , 2010, Journal of Lipid Research.

[20]  J. George.  Mechanisms of Disease: the evolving role of regulatory T cells in atherosclerosis , 2008, Nature Clinical Practice Cardiovascular Medicine.

[21]  J. Ordovás,et al.  Impact of genetic and environmental factors on hsCRP concentrations and response to therapeutic agents. , 2009, Clinical chemistry.

[22]  John C. Wilkinson,et al.  COMMD Proteins, a Novel Family of Structural and Functional Homologs of MURR1* , 2005, Journal of Biological Chemistry.

[23]  H. Tiwari,et al.  Apolipoprotein E Polymorphisms and Postprandial Triglyceridemia Before and After Fenofibrate Treatment in the Genetics of Lipid Lowering and Diet Network (GOLDN) Study , 2010, Circulation. Cardiovascular genetics.

[24]  T. Kilpatrick,et al.  Fine mapping of multiple sclerosis susceptibility genes provides evidence of allelic heterogeneity at the IL2RA locus , 2009, Journal of Neuroimmunology.

[25]  M. Province,et al.  Association of Common C-Reactive Protein (CRP) Gene Polymorphisms With Baseline Plasma CRP Levels and Fenofibrate Response , 2008, Diabetes Care.

[26]  N. Minato,et al.  Rap1 Functions as a Key Regulator of T-Cell and Antigen-Presenting Cell Interactions and Modulates T-Cell Responses , 2002, Molecular and Cellular Biology.

[27]  I. Borecki,et al.  TCF7L2 polymorphisms and inflammatory markers before and after treatment with fenofibrate , 2009, Diabetology & Metabolic Syndrome.

[28]  I. Borecki,et al.  The -256T>C polymorphism in the apolipoprotein A-II gene promoter is associated with body mass index and food intake in the genetics of lipid lowering drugs and diet network study. , 2007, Clinical chemistry.

[29]  A. West,et al.  A mutant collagen XIII alters intestinal expression of immune response genes and predisposes transgenic mice to develop B-cell lymphomas. , 2008, Cancer research.

[30]  Adrian Vella,et al.  Localization of a type 1 diabetes locus in the IL2RA/CD25 region by use of tag single-nucleotide polymorphisms. , 2005, American journal of human genetics.